First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:8024-8024
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Gettinger Scott N.¹,Shepherd Frances A.²,Antonia Scott Joseph³,Brahmer Julie R.⁴,Chow Laura Quan Man⁵,Juergens Rosalyn A.⁶,Borghaei Hossein⁷,Shen Yun⁸,Harbison Christopher⁸,Alaparthy Suresh⁸,Chen Allen C.⁸,Rizvi Naiyer A.⁹

Affiliation:

1. Yale Cancer Center, New Haven, CT

2. Princess Margaret Cancer Centre, Toronto, ON, Canada

3. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

4. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

5. University of Washington, Seattle, WA

6. Juravinski Cancer Centre, Hamilton, ON, Canada

7. Fox Chase Cancer Center, Philadelphia, PA

8. Bristol-Myers Squibb, Princeton, NJ

9. Memorial Sloan-Kettering Cancer Center, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.8024

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors;Cancer Immunology, Immunotherapy;2024-02-13

2. Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy;Cancer Research;2024-01-17

3. Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?;Journal of Clinical Medicine;2023-04-20

4. Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report;Current Oncology;2022-12-26

5. Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer;Medicina;2022-11-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3